

Cadila Healthcare Limited

Registered Office: Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015.

Tel. No. (+91-79) 2686 8100 Fax No.: (+91-79) 2686 2365/66 Website: www.zyduscadila.com

Audited Financial Results for the Quarter & year ended on March 31, 2010.

CONSOLTDATED COMPANY Rupees in Lacs [except for share data]
| Year to date | Year to date Rupees in Lacs [except for share data] Correspondin Correspondin figures for figures for figures for figures for Sr. No. g 3 Months the current g 3 Months 3 Months the previous 3 Months the current the previous Period ended Period ended vear ended vear ended Period ended Period ended vear ended vear ended on March 31, 2010 2009 2010 2009 2010 2009 2010 2009 Sales & Income from operations: 82.597 71.025 361.423 291,711 Gross Sales 43,065 43,610 185,491 173 744 4,005 Less : Excise Duty 1,008 770 5,471 В 490 549 2,198 3,892 81,589 70,255 357,418 286,240 Net Sales 42,575 43,061 183,293 169,852 3,068 11,267 Other Income from Operations 14,602 2.085 6,509 D 5,716 59,196 24,720 194,572 72,340 368,685 292,749 Total sales and other income from operations 57,177 48,777 242,489 84,657 Ε 2 Expenditure: Increase [-] / Decrease [+] in stock in trade & work in progress (5,044) 2,908 (11,334 (4.607)(1,870) 2.622 (1,080) 1.792 27.952 15 587 97.889 66 946 R Consumption of materials 20,805 12 075 70.548 49 836 6,151 5,712 31.280 33,320 C Purchase of traded goods 118 2,542 7,319 13,350 10,821 7,497 44,059 35,208 D Employees cost 7,526 4,544 27,790 21.803 13,389 8,256 3,979 3,140 11,182 Е Depreciation, Amortisation & Impairment 2,464 2,286 9,004 25,842 25,721 125,924 101,304 Other Expenditure 15,863 16,650 76,924 65,763 190,505 G 44,906 69,701 60,565 301,207 243,353 Total Expenditure 40,719 160,800 3 Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2] 14,956 11.775 67,478 49,396 12,271 8.058 51,984 33.772 512 433 1,591 2.036 4 Other Income 847 879 4,351 5.953 15.468 12 208 69.069 51 432 5 Profit before Interest & Exceptional Items [3+4] 13.118 8 937 56.335 39 725 Interest & financial charges 1,575 4,399 8,092 9,778 6 Α 906 3.236 4,263 7,288 (1,290) 122 2,270 Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans (127 1,514 111 В 112 45 1,686 3,109 8,214 12,048 Total Financial cost 779 3,348 4,308 8,802 13,782 9.099 60,855 39,384 Profit after Interest but before Exceptional Items [5 - 6] 12,339 5,589 52,027 30.923 Exceptional Items [+] Income / [-] Expense (2,226) (464) (2,408)8 (1,282)(1,282)0 0 0 13,782 60,391 9 Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8] 12,339 52,027 6.873 36.976 4,307 29,641 677 1.582 7,407 6.658 10 Tax expense (760 50 1,700 3.050 13,105 5.291 52,984 30.318 11 Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 -10] 13,099 4 257 50,327 26,591 12 Extraordinary items [net of tax expense] 0 0 0 0 0 0 0 0 13.105 5,291 52.984 30.318 13 Net Profit [+] / Loss [-] for the period [11 - 12] 13,099 4,257 50,327 26.591 (1,229 509 (2,470) (10) 14 Adjustments on consolidation [+] Income / [-] Expense 0 0 11,876 5.800 50,514 30,308 15 Net Profit [+] / Loss [-] for the period [13 + 14] 13,099 4,257 50,327 26.591 6,824 6.824 6.824 16 6.824 6.824 6,824 Paid-up equity share capital [Face Value Rs. 5 /-] 6,824 6.824 156,030 116,700 17 Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year 155,390 116,460 Earnings Per Share [EPS] [For the period - not Annualised]: 18 8.70 4 25 37.01 22 20 Basic & Diluted EPS before & after Extraordinary items [Rs.] 9.60 3 12 36.87 19 48 5.80 2.83 24.67 14.80 R Adjusted Basic & Diluted EPS before & after Extraordinary items [Rs.] 6.40 2.08 24.58 12 99 19 Public shareholding : 34,406,982 34,629,818 34,406,982 34,629,818 Number of shares 34,406,982 34,629,818 34,406,982 34,629,818 25.21% 25.21% Percentage of Shareholding 25.21% 25.37% 25.21% 20 Promoters and Promoter group Shareholding: Pledged / Encumbered : Α Nil Ni Nil Nil Number of Shares Nil Nil Nil Nil N.A NΑ N.A NΑ Percentage of shares [as a % of the total shareholding of promoters and promoter group] N.A NΑ N.A. NΑ N.A NΑ N.A N.A Percentage of shares [as a % of the total share capital of the company] N.A N.A N.A NΑ Non-encumbered: 102,092,031 101,869,195 102,092,031 101,869,195 102,092,031 101,869,195 Number of Shares 102,092,031 101,869,195 100% 100% 100% Percentage of shares [as a % of the total shareholding of promoters and promoter group] 100% 100.00% 100% 74.79% 74.63% 74.79% 74.63% Percentage of shares [as a % of the total share capital of the company] 74.79% 74.63% 74.79% 74.63%

Notes :

- [1] Pursuant to the amendments to Clause 41 of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standalone results of the company on the company's website: www.zyduscadila.com and/or on the websites of BSE [www.bseindia.com] and/or NSE [www.nseindia.com].
- [2] The above results for the quarter / year ended on March 31, 2010 were reviewed by the Audit Committee on April 28, 2010 and then approved by the Board of Directors at their meeting held on April 29, 2010.
- [3] In Consolidated Accounts, the accounts of foreign subsidiaries / a Joint Venture Company are audited up to December 31, 2009 / February 28, 2010 and subject to limited review by their auditors for the balance period upto March 31, 2010 whereever applicable.
- [4] The Bonus Committee at its meeting held on April 9, 2010 has allotted 68,249,507 Equity Shares of Rs. 5/- each fully paid-up as Bonus Shares in the ratio of one equity share for every two equity shares held by the members on the Record Date fixed for the purpose by capitalisation of Security Premium Account and General Reserves. Therefore the paid-up share capital of the Company is increased to 204,748,520 Equity Shares of Rs. 5/- each fully paid-up.
- [5] Zydus Animal Health Limited [ZAHL], a wholly owned subsidiary has pursuant to High Court order reduced its paid-up equity share capital from Rs. 54 Crores to Rs. 24 Crores by cancelling 30,000,000 Equity Shares of Rs. 10/- each fully paid- up aggregating to Rs. 30 Crores. Accordingly the investment of the Company in ZAHL has been reduced to that extent.
- [6] The Board of Directors have recommended a dividend of Rs. 5/- per equity share [@ 100%] on the increased capital of 204,748,520 equity shares (including 68,249,507 Bonus equity shares) of Rs.5/- each for the financial year ended on March 31, 2010.
- [7] The changes in Investments during the quarter are as under :
 - [A] Zydus Technologies Limited [Additional Investment]
 - [B] Zydus BSV Pharma Pvt. Limited [Additional Investment]

Rs. 5065 Lacs Rs. 65 Lacs

[8] The status of investor complaints :

Pending at the beginning of the quarter - Nil, received during the quarter - 21, disposed off during the quarter - 20, pending at the end of the quarter - 1.

[9] The Company has one segment of activity viz., "Pharmaceuticals".

For Cadila Healthcare Limited.

Pankaj R. Patel Chairman & Managing Director